The legacy status of Viagra, and this parent firm copyright, presents a challenging question for shareholders . While profits initially surged, the impending patent lapse and rising generic rivalry https://janicedera028928.techionblog.com/41752803/the-blue-pill-and-big-pharma-a-uncertain-investment